Dr. Rafal P. Witek, a KOL in the hepatocyte sector, reviews selection criteria and source of variabilities, including donor variabilities, process variabilities and functional stability, that impact performance of cryopreserved primary hepatocytes when used in in vitro cell culture. Different criteria for 2D and 3D use will be covered to enable participants to understand how to select the best performing primary hepatocyte lots for their studies. In addition, the webinar will cover best practices when handling primary hepatocytes during storage, after thawing, during plating and during 3D aggregation to overcome challenges related to data reproducibility and variability.

Dr. Witek is a highly accomplished interdisciplinary scientist with over 24 years of work history in industry and academia. Currently, he is a freelance consultant supporting liver biology and biotechnology for pre-clinical development and advancement of therapeutic cell and gene therapy technologies for liver failure and liver metabolic disorders. Prior, Dr. Witek was the VP of Translational Sciences and Head of the Liver Program at Aspect Biosystems, in Vancouver, British Columbia, Canada. During that time, he led the development of 3D bio-printed implantable liver microtissues for treatment of liver failure and monogenic/metabolic liver disorders.

To learn more about AnaBios and our superior quality human hepatocytes, visit www.anabios.com.